Clinical Trial Update: Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating trametinib and ponatinib in KRAS-mutant advanced non-small cell lung cancer has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iclusig (ponatinib)
• MEKINIST (trametinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non Small Cell Lung Cancer, KRAS Gene Mutation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-09-21